{"product_id":"clinical-exome-sequencing-ces-trio_onco-with-mcc","title":"Clinical Exome Sequencing (CES) -TRIO_ONCO With MCC","description":"\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003cdiv class=\"relative flex min-h-0 w-full flex-1 flex-col self-end\"\u003e\n\u003cdiv class=\"relative flex min-h-0 flex-auto flex-col overflow-hidden border-t transition-colors border-transparent\"\u003e\n\u003csection class=\"popover flex h-full w-full flex-col bg-transparent\"\u003e\n\u003csection class=\"relative flex min-h-0 flex-auto grow flex-col overflow-hidden\"\u003e\n\u003cdiv class=\"block h-auto\"\u003e\n\u003cdiv class=\"h-full w-full\"\u003e\n\u003cdiv class=\"flex h-full justify-center\"\u003e\n\u003cdiv class=\"z-0 flex w-full flex-col items-center\"\u003e\n\u003cdiv id=\"prosemirror-context-children\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"relative z-10 flex max-w-full h-fit\" id=\"prosemirror-editor-container\"\u003e\n\u003cdiv class=\"_9XkC5G_main z-10 markdown prose dark:prose-invert contain-inline-size focus:outline-hidden bg-transparent ProseMirror\" translate=\"no\"\u003e\n\u003ch1\u003e\u003cbr\u003e\u003c\/h1\u003e\n\u003ch1\u003e\u003cspan\u003eClinical Exome Sequencing (CES) – TRIO_ONCO with MCC\u003c\/span\u003e\u003c\/h1\u003e\n\u003ch2\u003e\u003cspan\u003eAdvanced Comprehensive Genomic Testing for Oncology \u0026amp; Hereditary Cancer Evaluation\u003c\/span\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cspan\u003eTest Name\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eClinical Exome Sequencing (CES) – TRIO_ONCO with MCC\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eOverview\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cspan\u003eClinical Exome Sequencing (CES) – TRIO_ONCO with MCC is an advanced next-generation sequencing (NGS) based genomic test designed to identify clinically relevant genetic variations associated with hereditary cancers, tumor predisposition syndromes, and precision oncology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis comprehensive assay evaluates coding regions of clinically significant genes and enables simultaneous assessment of:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\u003cspan\u003eGermline mutations\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eSomatic variants\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eInherited cancer syndromes\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eRare oncogenic alterations\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eTherapy-guiding biomarkers\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eFamilial segregation analysis through Trio evaluation\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThe TRIO approach analyzes samples from:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\u003cspan\u003ePatient \/ Proband\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eBiological Mother\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eBiological Father\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThis improves variant interpretation accuracy and supports better clinical decision-making.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eMCC (Maternal Cell Contamination) analysis enhances sample quality assessment and improves analytical confidence in specific specimen types.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eTechnology Platform\u003c\/span\u003e\u003c\/h1\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\u003cspan\u003eNext Generation Sequencing (NGS)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eClinical Exome Sequencing Technology\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eHigh-depth coverage sequencing\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAdvanced bioinformatics pipeline\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eACMG-guided variant classification\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eAI-assisted genomic interpretation\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eClinical Applications\u003c\/span\u003e\u003c\/h1\u003e\n\u003ch2\u003e\u003cspan\u003eOncology Applications\u003c\/span\u003e\u003c\/h2\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\u003cspan\u003eHereditary cancer risk assessment\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eEarly-onset cancers\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eFamilial cancer syndromes\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePrecision oncology profiling\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eTherapy selection guidance\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePrognostic marker identification\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eTumor predisposition evaluation\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eRare cancer gene detection\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cspan\u003eCommonly Associated Conditions\u003c\/span\u003e\u003c\/h2\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\u003cspan\u003eBreast Cancer\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eOvarian Cancer\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eColorectal Cancer\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eProstate Cancer\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePancreatic Cancer\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eEndometrial Cancer\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eHematological Malignancies\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePediatric Cancers\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eNeuroendocrine Tumors\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eSarcoma Syndromes\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eGenes \u0026amp; Variant Analysis\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp\u003e\u003cspan\u003eThe assay evaluates clinically relevant genes associated with:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\u003cspan\u003eDNA repair pathways\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eTumor suppressor genes\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eOncogenes\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eCell-cycle regulation\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eHereditary cancer syndromes\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003ePharmacogenomic markers\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eImmunotherapy-related biomarkers\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eVariant types analyzed include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\u003cspan\u003eSingle Nucleotide Variants (SNVs)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eInsertions \u0026amp; Deletions (Indels)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eCopy Number Variations (CNVs)\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eSplice-site variants\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eClinically significant exonic alterations\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv\u003e\u003chr\u003e\u003c\/div\u003e\n\u003ch1\u003e\u003cspan\u003eAdvantages of TRIO Analysis\u003c\/span\u003e\u003c\/h1\u003e\n\u003cul data-spread=\"false\"\u003e\n\u003cli\u003e\u003cspan\u003eImproved variant interpretation\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eBetter differentiation of inherited vs de novo variants\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eIncreased diagnostic yield\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eReduced uncertain findings\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eEnhanced genetic counseling support\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cspan\u003eSuperior family-based genomic analysis\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Lifecell Diagnostics","offers":[{"title":"Default Title","offer_id":44007228407943,"sku":null,"price":37730.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0691\/4241\/3447\/files\/e89d5f19-49b5-45b9-ba77-a70663bf64b8.png?v=1779778719","url":"https:\/\/ourdermastore.com\/products\/clinical-exome-sequencing-ces-trio_onco-with-mcc","provider":"Ourdermastore ","version":"1.0","type":"link"}